| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC22A18 |
| Uniprot No | Q96BI1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-424 aa |
| 活性数据 | MQGARAPRDQGQSPGRMSALGRSSVILLTYVLAATELTCLFMQFSIVPYLSRKLGLDSIAFGYLQTTFGVLQLLGGPVFGRFADQRGARAALTLSFLAALALYLLLAAASSPALPGVYLLFASRLPGALMHTLPAAQMVITDLSAPEERPAALGRLGLCFGVGVILGSLLGGTLVSAYGIQCPAILAALATLLGAVLSFTCIPASTKGAKTDAQAPLPGGPRASVFDLKAIASLLRLPDVPRIFLVKVASNCPTGLFMVMFSIISMDFFQLEAAQAGYLMSFFGLLQMVTQGLVIGQLSSHFSEEVLLRASVLVFIVVGLAMAWMSSVFHFCLLVPGLVFSLCTLNVVTDSMLIKAVSTSDTGTMLGLCASVQPLLRTLGPTVGGLLYRSFGVPVFGHVQVAINTLVLLVLWRKPMPQRKDKVR |
| 分子量 | 71.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为关于重组人SLC22A18蛋白的参考文献示例(注：以下内容为示例，实际文献需通过学术数据库获取)：
---
1. **《SLC22A18 as a potential tumor suppressor in multiple cancers》**
*作者: Smith A, et al. (2015)*
**摘要**: 研究揭示了SLC22A18在乳腺癌和肺癌中的表达显著下调，并通过重组蛋白实验表明其过表达可抑制肿瘤细胞增殖，提示其可能通过调控有机分子转运发挥抑癌作用。
2. **《Functional characterization of recombinant SLC22A18 as a polyspecific organic cation transporter》**
*作者: Zhang Y, et al. (2018)*
**摘要**: 利用HEK293细胞表达重组SLC22A18蛋白，证实其可转运多种有机阳离子底物，提示其在药物代谢和细胞信号传导中的潜在功能。
3. **《Structural insights into SLC22A18 through cryo-EM analysis》**
*作者: Tanaka K, et al. (2021)*
**摘要**: 通过冷冻电镜技术解析重组人SLC22A18蛋白的三维结构，揭示了其跨膜结构域特征及底物结合位点，为理解其转运机制提供分子基础。
4. **《Epigenetic silencing of SLC22A18 promotes chemoresistance in colorectal cancer》**
*作者: Lee H, et al. (2020)*
**摘要**: 研究发现结直肠癌中SLC22A18的表观遗传沉默导致化疗耐药，重组蛋白表达实验表明恢复其功能可增强癌细胞对5-氟尿嘧啶的敏感性。
---
建议通过PubMed、Web of Science等平台以关键词“recombinant SLC22A18”或“SLC22A18 protein function”检索最新文献。部分研究可能侧重基因层面，需筛选涉及蛋白重组表达的内容。
**Recombinant Human SLC22A18 Protein**
SLC22A18 (Solute Carrier Family 22 Member 18), also known as ORCTL2 or BWR1A, is a poorly characterized member of the SLC22 family of transmembrane transporter proteins. This family primarily facilitates the movement of organic ions, metabolites, and drugs across cellular membranes. SLC22A18 is mapped to chromosome 11p15.5. a genomic region associated with imprinting disorders and tumor suppression. It is maternally expressed and implicated in cancer biology, particularly as a potential tumor suppressor in certain malignancies, including lung, breast, and ovarian cancers. Epigenetic silencing via promoter hypermethylation has been observed in tumor tissues, correlating with dysregulated cell proliferation and apoptosis.
Structurally, SLC22A18 is predicted to contain 12 transmembrane domains, typical of SLC transporters, though its exact substrates and physiological roles remain unclear. Studies suggest involvement in nucleoside transport or cellular osmolyte regulation, potentially influencing metabolic homeostasis.
Recombinant human SLC22A18 protein, produced via heterologous expression systems like *E. coli* or mammalian cells, enables functional studies to clarify its transport mechanisms, interactions, and pathological relevance. Its role in cancer and imprinting-related diseases makes it a candidate for therapeutic targeting or biomarker development. Further research is required to unravel its precise biological functions and therapeutic potential.
×
